Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roginolisib + dostarlimab ± docetaxel in advanced non-squamous NSCLC
NCT06879717Phase 2Active, not recruiting
- Sponsor
- iOnctura
- Start
- Apr 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of roginolisib in non-small cell lung cancer (NSCLC), sponsored by iOnctura. Started Apr 2025; status: active, not recruiting.
02
Drugs
roginolisib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06879717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06879717.